Delta-Fly Pharma, Inc.
4598.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.82 | 0.20 | -0.08 | 0.72 |
| FCF Yield | -36.26% | -29.59% | -38.21% | -28.84% |
| EV / EBITDA | -2.75 | -2.08 | -1.94 | -2.08 |
| Quality | ||||
| ROIC | -614.92% | -113.86% | -166.31% | -77.97% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 100.00% |
| Cash Conversion Ratio | 1.07 | 0.90 | 0.98 | 0.98 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% | 6,694,229.50% |
| Free Cash Flow Growth | -43.25% | 1.74% | -38.60% | -29.33% |
| Safety | ||||
| Net Debt / EBITDA | 0.20 | 1.01 | 0.64 | 1.32 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -511.69 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |